As much as 96% of customers and 60% of patients can get their results in less than a minute with Retinalyze, according to the company.
RetinaLyze System A/S has unveiled an advanced glaucoma progression artificial intelligence (AI), which works to offer a stable and consistent method for tracking glaucoma over time.1 The Glaucoma Index of Progression (GIP) provides the ability to detect glaucoma early by measuring subtle changes in disease progression and status, according to a news release.
GIP also features the ability to compare changes in both eyes simultaneously, allowing eye care providers to examine GIP indices along the estimated areas of the optic cup and rim sectors. This can then facilitate a better understanding of the progression or regression affecting the optic nerve and surrounding structures in the eye.1
RetinaLyze is a screening software that utilizes an automated algorithm module to detect signs of eye disease by analyzing fundus images and OCT scans via pathology detection. It can be used as a clinical decision support system or as a screening tool in conjunction with a telemedicine module.2
According to RetinaLyze System A/S CCO Ganesh Ram, 96% of customers and 60% of patients can get their results in less than a minute, in addition to streamlining referral for patients.3 “By using the system, what you’re doing is you’re lowering the risk of referring erroneous results, so you’re not forwarding too many false positive to the local ophthalmologists,” he said in a presentation.
Additionally, larger optometric retailers can integrate the AI tool in about 6 months, with smaller private practice able to get RetinaLyze running in a week.3
Free trials of the AI tool are available here.